Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cell Line, Tumor
Chlorophyllides
Cisplatin
/ administration & dosage
Combined Modality Therapy
Drug Delivery Systems
Head and Neck Neoplasms
/ pathology
Humans
Male
Metformin
/ administration & dosage
Mice, Inbred BALB C
Multifunctional Nanoparticles
/ administration & dosage
Photochemotherapy
Phototherapy
/ methods
Polyethylene Glycols
/ chemistry
Porphyrins
/ chemistry
Squamous Cell Carcinoma of Head and Neck
/ pathology
Tumor Hypoxia
/ drug effects
Xenograft Model Antitumor Assays
chlorin e6
cisplatin
head and neck squamous cell carcinoma
metformin
nano-delivery
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
10
2019
accepted:
09
01
2020
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
19
5
2020
Statut:
epublish
Résumé
Chemotherapy in head and neck squamous cell carcinoma (HNSCC) has many systemic side effects, as well as hypoxia-induced chemoresistance. To reduce side effects and enhance chemosensitivity are urgently needed. We synthesized a drug delivery system (named CECMa NPs) based on cisplatin (CDDP) and metformin (chemotherapeutic sensitizer), of which chlorin e6 (Ce6) and polyethylene glycol diamine (PEG) were synthesized as the shell, an anti-LDLR antibody (which can target to hypoxic tumor cells) was modified on the surface to achieve tumor targeting. The NPs possessed a great synergistic effect of chemotherapy and phototherapy. After laser stimulation, both CDDP and metformin can be released in situ to achieve anti-tumor effects. Meanwhile, PDT and PTT triggered by a laser have anticancer effects. Furthermore, compared with free cisplatin, CECMa exhibits less systemic toxicity with laser irradiation in the xenograft mouse tumor model. CECMa effectively destroyed the tumors via hypoxia targeting multimodal therapy both in vitro and in vivo, thereby providing a novel strategy for targeting head and neck squamous cell carcinoma.
Identifiants
pubmed: 32021184
doi: 10.2147/IJN.S233294
pii: 233294
pmc: PMC6980849
doi:
Substances chimiques
Chlorophyllides
0
Porphyrins
0
Polyethylene Glycols
3WJQ0SDW1A
phytochlorin
5S2CCF3T1Z
Metformin
9100L32L2N
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-361Informations de copyright
© 2020 Song et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Biomed Mater Res B Appl Biomater. 2019 Nov;107(8):2658-2663
pubmed: 30864237
Int J Nanomedicine. 2018 Jul 04;13:3921-3935
pubmed: 30013345
Drug Resist Updat. 2016 Jan;24:34-54
pubmed: 26830314
Cancer Med. 2018 May 15;:null
pubmed: 29761938
Nano Lett. 2009 Oct;9(10):3651-7
pubmed: 19736912
Oral Oncol. 2017 Aug;71:150-155
pubmed: 28688683
Nat Commun. 2019 Mar 22;10(1):1336
pubmed: 30902997
J Am Chem Soc. 2014 Oct 22;136(42):15010-5
pubmed: 25290917
Oncotarget. 2016 Jun 21;7(25):37773-37789
pubmed: 27191981
Oncogene. 2018 Feb 15;37(7):873-883
pubmed: 29059160
ACS Nano. 2019 Feb 26;13(2):1253-1271
pubmed: 30633492
Oral Oncol. 2012 Mar;48(3):266-71
pubmed: 22079100
Head Neck. 2013 Sep;35(9):1362-70
pubmed: 22941934
Theranostics. 2018 Oct 22;8(19):5259-5275
pubmed: 30555545
Mol Cancer. 2017 Jun 21;16(1):106
pubmed: 28633632
J Photochem Photobiol B. 2019 Mar;192:19-25
pubmed: 30665146
ACS Chem Biol. 2013 Jan 18;8(1):127-32
pubmed: 23092119
Cancer Lett. 2016 Sep 28;380(1):203-4
pubmed: 27060765
J Am Chem Soc. 2015 Feb 11;137(5):1947-55
pubmed: 25597855
Pharmacol Res. 2019 May;143:178-185
pubmed: 30611856
Biomater Sci. 2019 Jun 25;7(7):2749-2758
pubmed: 30997445
ChemMedChem. 2019 Jul 17;14(14):1315-1320
pubmed: 31207080
Acta Oncol. 2013 Jun;52(5):1002-9
pubmed: 22950385
J Am Chem Soc. 2013 Mar 27;135(12):4799-804
pubmed: 23495667
Mol Cancer Ther. 2010 May;9(5):1092-9
pubmed: 20442309
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Clin Transl Oncol. 2017 Jun;19(6):769-776
pubmed: 28120324
Lasers Med Sci. 2014 Mar;29(2):847-53
pubmed: 23917412
Curr Med Chem. 2017;24(39):4399-4416
pubmed: 28799495
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941